Home › Therapeutic areas › Oncology › Breast Cancer
Breast Cancer (24 companies)
Companies with an active program in Breast Cancer.
| Ticker | Company | Therapeutic areas | Programs | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| AKTS | Aktis Oncology | Oncology | 1 | Phase 1 | $880M | 10 |
| ANIX | Anixa Biosciences | Oncology | 1 | Phase 1 | $111M | 3 |
| ARTV | Artiva Biotherapeutics | Oncology | 1 | — | $203M | 6 |
| ARVN | Arvinas | NeurologyOncology Rare | 1 | Approved | $420M | 10 |
| BCTX | BriaCell Therapeutics | Oncology | 3 | Phase 3 | $34.5M | 8 |
| CLRB | Cellectar Biosciences | Oncology | 1 | Phase 2 | $11.8M | 6 |
| CMPX | Compass Therapeutics | Oncology | 1 | Phase 2 | $137M | 15 |
| CYDY | CytoDyn | NeurologyOncology | 1 | Phase 2 | $338M | 3 |
| EIKN | Eikon Therapeutics | Oncology | 2 | Phase 2 | $320M | 13 |
| FHTX | Foghorn Therapeutics | Oncology | 1 | Preclinical | $111M | 4 |
| GLSI | Greenwich LifeSciences | Oncology | 1 | Phase 3 | $223M | 1 |
| IDYA | IDEAYA Biosciences | Oncology | 2 | NDA Submitted | $3.02B | 14 |
| IBRX | ImmunityBio | Infectious DiseaseOncology | 1 | Approved | $9.15B | 16 |
| IMNM | Immunome | Oncology Rare | 1 | NDA Submitted | $2.13B | 9 |
| KAPA | Kairos Pharma | Oncology | 1 | Phase 2 | — | 13 |
| KZIA | Kazia Therapeutics | NeurologyOncology Rare | 2 | Phase 2 | $82.0M | 13 |
| GLUE | Monte Rosa Therapeutics | CardiovascularDermatology+3 Rare | 1 | Phase 2 | $903M | 7 |
| OLMA | Olema Pharmaceuticals | Oncology | 2 | Phase 3 | $641M | 3 |
| OKUR | OnKure Therapeutics | Oncology | 1 | Preclinical | $116M | 2 |
| ORIC | Oric Pharmaceuticals | Oncology | 1 | Phase 3 | $914M | 5 |
| PMVP | PMV Pharmaceuticals | Oncology | 1 | Phase 2 | $67.4M | 7 |
| PRLD | Prelude Therapeutics | HematologyOncology Rare | 1 | Phase 1 | $287M | 3 |
| RLAY | Relay Therapeutics | DermatologyOncology Rare | 1 | Approved | $4.11B | 4 |
| VIR | Vir Biotechnology | Infectious DiseaseOncology Rare | 1 | Phase 3 | $2.09B | 12 |
No companies match.